Successful use of trastuzumab deruxtecan in hepatic visceral crisis secondary to metastatic HER2-low breast cancer

•Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and death.•Combination chemotherapy is recommended for hepatic visceral crisis however the outcomes are generally dismal.•Trastuzumab deruxtecan is...

Celý popis

Podrobná bibliografie

Vydáno v:	Current problems in cancer. Case reports Ročník 20; s. 100392
Hlavní autoři:	Kapoor, Nilesh, Su, Malcolm, Horadam, Rochelle, Klemow, Dawn, Syed, Samira
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Elsevier Inc 01.12.2025
Témata:	Antibody-drug conjugate Hematology, Oncology, and Palliative Medicine Hepatic visceral crisis HER2-low Metastatic breast cancer Trastuzumab deruxtecan Metastatic breast cancer HER2-low Trastuzumab deruxtecan Hepatic visceral crisis Antibody-drug conjugate
ISSN:	2666-6219, 2666-6219
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!